Search

Meet Zhongmin Wang, a fifth-year doctoral student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), who has been awarded the 2021 Chairman’s Prize.

… Wednesday, September 22, 2021 Zhongmin Wang , a fifth-year doctoral student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), has been awarded the 2021 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Louis

During the upcoming ASCO Virtual Scientific Program, MSK Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD, will present a study that found pembrolizumab addition to first-line chemotherapy significantly improved progression-free survival for patients with small cell lung cancer (SCLC).

… Thursday, May 28, 2020 Dr. Charles Rudin Dr. Charles Rudin At the American Society of Clinical Oncology (ASCO) Virtual Scientific Program , Memorial Sloan Kettering (MSK) Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD , will present a study that found pembrolizumab addition to first-line

Learn how MSK’s Antibiotic Management Program is leading the way in ensuring that antibiotics and other antimicrobial drugs are used responsibly.

… Wednesday, May 22, 2019 Summary In this Q & A, infectious disease expert Susan Seo discusses MSK’s Antibiotic Management Program. It ensures that antibiotics and other antimicrobial drugs are used responsibly. The rapid emergence of drug-resistant microorganisms is “a global crisis that threatens a century

MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2024 Marie-Josée Kravis Women in Science Endeavor (Kravis WISE) fellowship grant recipients.

… Thursday, February 29, 2024 Each year, the Marie-Josée Kravis Women in Science Endeavor (WISE) initiative awards several fellowships to female graduate students and postdoctoral fellows to support their research at Memorial Sloan Kettering Cancer Center (MSK). The awards are announced in March, to coincide

… Wednesday, March 5, 2025 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce a new community mural, “One Hundred Views,” by artist Naomi Reis. The inaugural MSK mural was created in collaboration with fifth-grade students from  P.S. 183 Robert L. Stevenson Elementary School , the neighboring

In a new study, MSK researchers looked at why glioblastoma brain tumors usually come back after treatment. Their findings suggest that a subset of cells — cancer stem cells — are able to evade current treatments because they are not actively dividing, and that these cells later form new tumors.

… Tuesday, January 11, 2022 Glioblastoma brain tumors are one of the most deadly forms of cancer, with a five-year survival rate of less than 10% for patients 45 and older. Even when the tumors look as if they have been fully removed, they almost always come back. Investigators who are part of Memorial

MSK studies presented at the 2022 American Association for Cancer Research meeting include updates on a targeted therapy for lung cancer, lab research on combining statins with a breast cancer drug, and a new tool for diagnosing blood cancer.

… Monday, April 11, 2022 Dozens of investigators from Memorial Sloan Kettering Cancer Center (MSK) shared their research at the 2022 American Association for Cancer Research (AACR) annual meeting, held April 8 to 13 in New Orleans. The studies presented included: A clinical trial that looked at the long-term

Collaboration will enhance innovation and the adoption of AI in translational research with the goal of improving patient care and outcomes.

… Monday, February 17, 2025 Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN) and Memorial Sloan Kettering Cancer Center (MSK), a leading global cancer center, today announced a collaboration harnessing the power of artificial intelligence (AI), high performance computing (HPC), and

New MSK research identifies a gene mutation associated with resistance to breast cancer treatment; reports encouraging results for expanding use of a new prostate cancer radiotherapy; determines the best radiation level for avoiding complications treating spinal tumors; and finds that proton therapy is effective against previously treated head and neck cancers.

… Tuesday, October 15, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) identifies a gene mutation associated with resistance to breast cancer treatment, as well as a possible strategy for overcoming the resistance; reports encouraging results for expanding use of a new prostate cancer

New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.

… Thursday, March 9, 2023 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — a hub for basic science and translational research within MSK — offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial